Dr Fintan Walton, CEO and Founder of PharmaVentures, conducted the following interviews for PharmaTV during the AusBiotech 2015 national conference.
Anna Lavelle, CEO of Ausbiotech, discusses the positive impact that recent political and legislative changes have had on Australia’s burgeoning biotech industry.
Julie Phillips, Executive Director, BioDiem Ltd, discusses the work of their subsidiary company Opal Biosciences, who are developing a small molecule anti-microbial compound for drug-resistant infections.
During AusBiotech 2015 Dr Paul MacLeman, Managing Director, IDT Australia Ltd, was interviewed by Dr Fintan Walton. IDT have over 30 years of experience in contract manufacturing.
During AusBiotech 2015 Dr Mark Ashton, Senior Director, Commercial Engagement, Health, UniQuest Pty Ltd, was interviewed by Dr Fintan Walton.
Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma Ltd, discusses Benitec’s unique gene-silencing technology.
Bill Ketelbey, CEO and Managing Director of Actinogen Ltd, discusses the development of their lead compound Xanamem™ , currently in clinical trials for the treatment of neurodegenerative diseases.
Cliff Holloway, CEO, Sienna Cancer Diagnostics Ltd, discusses the development and commercialisation of SCE-A7, the first telomerase detection product.
Gary Philips, CEO, Pharmaxis Ltd, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.
Paul Anderson, Managing Director of Orthocell Ltd, reveals the unique technology behind their versatile therapy for tendon and soft-tissue injuries.
During AusBiotech 2015 Dr Sean Parsons, Managing Director, Ellume Pty Ltd was interviewed by Dr Fintan Walton.